These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
835 related articles for article (PubMed ID: 34048946)
1. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC. Herbst RS; Garon EB; Kim DW; Cho BC; Gervais R; Perez-Gracia JL; Han JY; Majem M; Forster MD; Monnet I; Novello S; Gubens MA; Boyer M; Su WC; Samkari A; Jensen EH; Kobie J; Piperdi B; Baas P J Thorac Oncol; 2021 Oct; 16(10):1718-1732. PubMed ID: 34048946 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994 [TBL] [Abstract][Full Text] [Related]
3. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. Herbst RS; Garon EB; Kim DW; Cho BC; Perez-Gracia JL; Han JY; Arvis CD; Majem M; Forster MD; Monnet I; Novello S; Szalai Z; Gubens MA; Su WC; Ceresoli GL; Samkari A; Jensen EH; Lubiniecki GM; Baas P J Clin Oncol; 2020 May; 38(14):1580-1590. PubMed ID: 32078391 [TBL] [Abstract][Full Text] [Related]
4. KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. Ren S; Feng J; Ma S; Chen H; Ma Z; Huang C; Zhang L; He J; Wang C; Zhou J; Danchaivijtr P; Wang CC; Vynnychenko I; Wang K; Orlandi F; Sriuranpong V; Li B; Ge J; Dang T; Zhou C Int J Cancer; 2023 Aug; 153(3):623-634. PubMed ID: 37141294 [TBL] [Abstract][Full Text] [Related]
5. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. Herbst RS; Baas P; Perez-Gracia JL; Felip E; Kim DW; Han JY; Molina JR; Kim JH; Dubos Arvis C; Ahn MJ; Majem M; Fidler MJ; Surmont V; de Castro G; Garrido M; Shentu Y; Emancipator K; Samkari A; Jensen EH; Lubiniecki GM; Garon EB Ann Oncol; 2019 Feb; 30(2):281-289. PubMed ID: 30657853 [TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866 [TBL] [Abstract][Full Text] [Related]
7. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. Nishio M; Takahashi T; Yoshioka H; Nakagawa K; Fukuhara T; Yamada K; Ichiki M; Tanaka H; Seto T; Sakai H; Kasahara K; Satouchi M; Han SR; Noguchi K; Shimamoto T; Kato T Cancer Sci; 2019 Mar; 110(3):1012-1020. PubMed ID: 30618179 [TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study. Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285 [TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. Gadgeel SM; Rodríguez-Abreu D; Halmos B; Garassino MC; Kurata T; Cheng Y; Jensen E; Shamoun M; Rajagopalan K; Paz-Ares L J Thorac Oncol; 2024 Aug; 19(8):1228-1241. PubMed ID: 38642841 [TBL] [Abstract][Full Text] [Related]
10. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study. de Castro G; Kudaba I; Wu YL; Lopes G; Kowalski DM; Turna HZ; Caglevic C; Zhang L; Karaszewska B; Laktionov KK; Srimuninnimit V; Bondarenko I; Kubota K; Mukherjee R; Lin J; Souza F; Mok TSK; Cho BC J Clin Oncol; 2023 Apr; 41(11):1986-1991. PubMed ID: 36306479 [No Abstract] [Full Text] [Related]
11. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303 [TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Herbst RS; Baas P; Kim DW; Felip E; Pérez-Gracia JL; Han JY; Molina J; Kim JH; Arvis CD; Ahn MJ; Majem M; Fidler MJ; de Castro G; Garrido M; Lubiniecki GM; Shentu Y; Im E; Dolled-Filhart M; Garon EB Lancet; 2016 Apr; 387(10027):1540-1550. PubMed ID: 26712084 [TBL] [Abstract][Full Text] [Related]
13. Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC. Doroshow DB; Wei W; Gupta S; Zugazagoitia J; Robbins C; Adamson B; Rimm DL J Thorac Oncol; 2021 Dec; 16(12):2139-2143. PubMed ID: 34455068 [TBL] [Abstract][Full Text] [Related]
14. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368 [TBL] [Abstract][Full Text] [Related]
16. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leal TA; Riess JW; Jensen E; Zhao B; Pietanza MC; Brahmer JR J Clin Oncol; 2021 Jul; 39(21):2339-2349. PubMed ID: 33872070 [TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. Boyer M; Şendur MAN; Rodríguez-Abreu D; Park K; Lee DH; Çiçin I; Yumuk PF; Orlandi FJ; Leal TA; Molinier O; Soparattanapaisarn N; Langleben A; Califano R; Medgyasszay B; Hsia TC; Otterson GA; Xu L; Piperdi B; Samkari A; Reck M; J Clin Oncol; 2021 Jul; 39(21):2327-2338. PubMed ID: 33513313 [TBL] [Abstract][Full Text] [Related]
18. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States. Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V J Med Econ; 2017 Feb; 20(2):140-150. PubMed ID: 27571538 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan. Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]